Edition:
India

Cipla Ltd (CIPL.BO)

CIPL.BO on Bombay Stock Exchange

533.95INR
18 May 2018
Change (% chg)

Rs-19.10 (-3.45%)
Prev Close
Rs553.05
Open
Rs553.10
Day's High
Rs557.40
Day's Low
Rs531.00
Volume
117,256
Avg. Vol
176,729
52-wk High
Rs663.00
52-wk Low
Rs479.00

Select another date:

BUZZ-India's Cipla posts biggest intraday gain in over 3 months on Q4 profit

** Cipla Ltd rises as much as 7.8 pct to 564.90 rupees - posts biggest intraday pct gain since Feb 8

Cipla posts fourth quarter profit, misses estimates

Cipla Ltd, India's second-biggest drugmaker by market capitalization, posted a fourth-quarter profit on Tuesday, but missed street estimates.

UPDATE 1-India's Cipla posts Q4 profit, misses estimates

May 22 Cipla Ltd, India's second-biggest drugmaker by market capitalization, posted a fourth-quarter profit on Tuesday, but missed street estimates.

India's Cipla posts Q4 profit

May 22 Cipla Ltd, India's second-biggest drugmaker by market capitalization, posted a fourth-quarter profit on Tuesday, but missed analysts' estimates.

BRIEF-India's Cipla Ltd Posts March Qtr Consol Profit

* MARCH QUARTER CONSOL NET PROFIT 1.79 BILLION RUPEES VERSUS LOSS OF 617.9 MILLION RUPEES LAST YEAR

BRIEF-Cipla Partners With Mannkind For Marketing, Distribution Of Afrezza In India

* PARTNERS WITH MANNKIND FOR EXCLUSIVE MARKETING, DISTRIBUTION OF AFREZZA IN INDIA

BRIEF-Mannkind And Cipla Enter An Exclusive Marketing And Distribution Agreement For Afrezza® In India

* MANNKIND AND CIPLA ENTER AN EXCLUSIVE MARKETING AND DISTRIBUTION AGREEMENT FOR AFREZZA® IN INDIA

BRIEF-India's Cipla Gets Final Nod For Generic Vazculep, Others

* GETS FINAL NOD FOR GENERIC VAZCULEP, GENERIC PHENYLEPHRINE HYDROCHLORIDE INJECTION USP, 10 MG/ML SINGLE-DOSE VIAL, GENERIC AROMASIN

BRIEF-Cipla's JV Saba Investment Completes Disinvestment Of Stake Held In Al Jabal For Drugs And Medical Appliances

* CO'S JV SABA INVESTMENT COMPLETED DISINVESTMENT OF 99 PERCENT STAKE HELD IN AL JABAL FOR DRUGS AND MEDICAL APPLIANCES CO Source text: http://bit.ly/2GsCYiw Further company coverage:

BRIEF-India's Cipla Says Unit Launches Authorized Generic Version Of Aloxi In U.S.

* SAYS ‍CO'S UNIT LAUNCHES AUTHORIZED GENERIC VERSION OF ALOXI IN U.S. Source text - http://bit.ly/2pEclNR Further company coverage:

Select another date: